NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.06 -0.16 (-0.22%) GOLD FUTURES
2,371.00 +1.70 (+0.07%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
53,775.62 +820.67 (+1.55%)
Quest Diagnostics Incorporated (QDI.F)
| Previous close | 128.40 |
| Open | 130.85 |
| Bid | 129.35 x 30000 |
| Ask | 129.55 x 30000 |
| Day's range | 130.85 - 130.85 |
| 52-week range | 113.65 - 132.55 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 14.834B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 19.07 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.77 (2.16%) |
| Ex-dividend date | 08 Jul 2024 |
| 1y target est | N/A |
- PR Newswire
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of the Haystack MRD™ tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted
- PR Newswire
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members.
- PR Newswire
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024.
